



HIV Treatment Program Drugs available through the BC-CfE Drug Treatment Program

The medications listed can be requested by completing and submitting an HIV Drug Treatment Program Prescription Request Form. Requests will be assessed according to established therapeutic guidelines and reviewed for safety. Additional clinical information may be requested. Eligible individuals will obtain, at no cost, medications offered by the BC-CfE's Drug Treatment Program.

Antiretroviral Drugs for HIV infection

Abacavir (generic equivalent of Ziagen®)
 Abacavir-lamivudine (generic equivalent of Kivexa®)
 Atazanavir (generic equivalent of Reyataz®)
 Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy®)
 Cabotegravir-rilpivirine (Cabenuva®)
 Darunavir (generic equivalent of Prezista®)
 Darunavir-cobicistat (Prezcobix®)
 Dolutegravir (Tivicay® or generic equivalent)
 Dolutegravir-abacavir-lamivudine (Triumeq®)
 Dolutegravir-lamivudine (Dovato®)
 Doravirine (Pifeltro®)
 Doravirine-lamivudine-tenofovir disoproxil fumarate (Delstrigo®)
 Efavirenz (generic equivalent of Sustiva®)
 Efavirenz-emtricitabine-tenofovir disoproxil fumarate (generic equivalent of Atripla®)
 Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide (Genvoya®)
 Elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate (Stribild®)
 Emtricitabine-tenofovir alafenamide (Descovy®)
 Emtricitabine-tenofovir disoproxil fumarate (generic equivalent of Truvada®)
 Etravirine (Intelence®)
 Lamivudine (generic equivalent of 3TC®)
 Lamivudine-zidovudine (generic equivalent of Combivir®)
 Lopinavir/ritonavir (Kaletra®)
 Maraviroc (Celsentri® or generic equivalent)
 Nevirapine (generic equivalent of Viramune®)
 Raltegravir (Isentress®, Isentress® HD)
 Rilpivirine (Edurant®)
 Rilpivirine-emtricitabine-tenofovir disoproxil fumarate (Complera®)
 Ritonavir (Norvir® or generic equivalent)
 Tenofovir disoproxil fumarate (generic equivalent of Viread®)
 Zidovudine (generic equivalent of Retrovir®)

Drugs for Selected AIDS-related Opportunistic Infections (OI's) covered by the Program*

Atovaquone — PJP: alternate prophylaxis and alternate treatment option for mild disease; CNS toxoplasmosis: alternate prophylaxis and alternate treatment option.
 Azithromycin — DMAC: prophylaxis (monotherapy) and treatment (with ethambutol).
 Cidofovir — CMV: alternate treatment of retinitis (IV infusion. Intravitreal cidofovir injections are contraindicated); acyclovir-resistant mucocutaneous HSV (topical, compounded).
 Clarithromycin — DMAC: prophylaxis (monotherapy) and treatment (with ethambutol).
 Ethambutol - DMAC: treatment (2nd drug)
 Filgrastim - for management of neutropenia resulting from HIV-related treatments
 Foscarnet — CMV: alternate treatment of retinitis or other organ system involvement (IV infusion, +/- intravitreal injections if immediate sight-threatening ocular lesions).
 Ganciclovir — CMV: treatment of retinitis or other organ system involvement (IV infusion, +/- intravitreal injections if immediate sight-threatening ocular lesions).
 Rifabutin — DMAC: 3rd drug in management of severe or suspected drug-resistant DMAC.
 Valganciclovir — CMV: treatment of retinitis (+/- intravitreal injections of ganciclovir or foscarnet if immediate sight-threatening ocular lesions. No IV formulation of valganciclovir).

Drugs through Health Canada's Special Access Program (SAP)

(availability contingent on SAP approval)

Albendazole, or alternative — Microsporidium (species dependent)

Nevirapine liquid (Viramune®) — for children

*Abbreviations/Footnotes:

- CMV: Cytomegalovirus
- CNS: central nervous system
- PJP: Pneumocystis jirovecii pneumonia
- DMAC: disseminated Mycobacterium avium complex
 - o consideration for addition of 4th drug for severe or suspected drug resistant DMAC
- HSV: Herpes simplex virus